Project Grant R56NS136172

Award Date 9/6/24
Completion Date 8/31/25
Dollars Obligated $600K
Funding Federal Agency
Office of the Director
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
This $1,120,805 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders federal grant program (CFDA 93.853), will support research to investigate how prior SARS-CoV-2 infection may increase the risk of vascular contributions to cognitive impairment and dementia (VCID). The research aims to: Determine how prior SARS-CoV-2 infection influences blood-brain barrier...
This federal Project Grant award of $801,329 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research at the University of Illinois to investigate the role of Wnt/beta-catenin signaling in maintaining blood-brain barrier integrity and its potential to reverse neurological disorders associated with SARS-CoV-2 infection. The 5-year project aims to determine...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $3,659,973 to the University of South Florida to investigate the molecular mechanisms underlying neurological sequelae, known as "Neuro-COVID", experienced by individuals following SARS-CoV-2 (COVID-19) infection. The research aims to characterize age-dependent COVID-19-induced tau pathology and cognitive decline in mouse models, identify key molecular targets such as FKBP51 and...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $4,164,187 to The Regents of the University of California, San Francisco (UCSF) to develop antigen-directed therapies for autoantibody-associated neuroinflammatory diseases. The key goals are to discover autoantibodies directed to cell surface antigens, deeply characterize their...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $634,622 to investigate the mechanisms by which SARS-CoV-2 infection causes neurological post-acute sequelae, known as "NeuroPASC." The key products and services to be delivered include: 1) Acquiring high-resolution, multi-contrast, quantitative ex vivo MRI and detailed...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $183,096 to the University of Maryland, Baltimore to study the structural, functional, and neurobehavioral consequences of COVID-19 infection in adolescents. The key products and services to be delivered include: Longitudinal neuroimaging, cognitive, and psychiatric symptom data analysis to identify brain morphometric, microstructural, and functional...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $797,157 to Yale University to conduct research aimed at understanding circuit dysfunction in individuals with neuropsychiatric manifestations of post-acute sequelae of SARS-CoV-2 infection (Neuro-PASC). The 5-year project, starting on December 1, 2024, will leverage Yale's Neurocovid Clinic and the COVID Mind Study to recruit...
This federal Project Grant award from the National Institutes of Health National Institute of Mental Health provides $6,499,884 to Yale University under the Mental Health Research Grants program (CFDA 93.242) to study the longitudinal nervous system consequences of SARS-CoV-2 in people with HIV-1 treated in early infection. The award will fund research from September 2022 to September 2025 to analyze pre- and post-COVID-19 data from a cohort of early antiretroviral therapy-treated people with...
This $5.1 million project grant from the National Institute of Mental Health (NIMH), part of the Department of Health and Human Services, supports research under the Mental Health Research Grants program (CFDA 93.242). The Massachusetts General Hospital will utilize its existing biobank of over 800 maternal blood and neonatal cord blood samples linked to clinical records to characterize the impact of maternal SARS-CoV-2 infection on fetal neurodevelopment. Researchers will analyze immune...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $384,772 to the University of Tennessee Health Science Center (UTHSC) from January 10, 2025 to November 30, 2028. The project aims to elucidate the cellular and molecular mechanisms by which SARS-CoV-2 infection alters neuronal activity and behavior in mice. Key objectives include determining whether SARS-CoV-2 infection induces neuronal...

This Project Grant award of $600,000 from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) supports research to elucidate the role of antibodies in the neurological effects of COVID-19, known as "NeuroCOVID-19". The overarching goal is to investigate how inflammatory immunoglobulin G (IgG) antibodies associated with SARS-CoV-2 infection may trigger activation and damage to brain cells and endothelial cells, leading to disruptions in brain homeostasis. The research will utilize well-characterized inflammatory and anti-inflammatory IgGs from COVID-19 patient samples to assess their effects on human induced pluripotent stem cell-derived brain cells. Additionally, the project will explore the potential role of inflammatory IgGs in brain homeostasis using a chimeric human brain/mouse model, and determine the involvement of inflammatory IgGs in COVID-19-associated autoimmune responses. The outcomes of this research have the potential to inform therapeutic interventions targeting the neurological complications of SARS-CoV-2 infection.

Generated 7/15/25, 8:58 AM